Home / Market News / $CTNM

$CTNM news and market catalysts

The 13 most recent market catalysts affecting $CTNM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

13 catalysts 5 high impact 3 bullish 8 bearish Biotechnology
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
Contineum Therapeutics, Inc. 12-Month Price Target Adjusted to $21.43
Contineum Therapeutics, Inc. (CTNM) has seen a slight downward revision in its average 12-month price target from $22.14 to $21.43, based on estimates from seven analysts. While th…
Nov 3, 2026 Corporate Catalyst Neutral Impact 75
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Contineum Therapeutics reported a net loss of $18.7 million for Q3 2026, wider than the $12.8 million loss in Q3 2025, primarily due to increased R&D expenses which rose to $16.0 m…
Oct 15, 2026 Corporate Catalyst Bullish Impact 55
Jones Trading Maintains Buy on Contineum Therapeutics, Raises Price Target to $30
Jones Trading analyst Debanjana Chatterjee has maintained a 'Buy' rating on Contineum Therapeutics and raised the price target from $24 to $30. This upgrade reflects a more optimis…
Oct 14, 2026 Corporate Catalyst Bearish Impact 65
Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14
Baird's downgrade of Contineum Therapeutics from Outperform to Neutral, coupled with a significant price target reduction from $19 to $14, signals a diminished outlook for the comp…
Oct 12, 2026 Corporate Catalyst Bearish Impact 85
Why Is Contineum Therapeutics Stock Falling Monday?
Contineum Therapeutics (CTNM) stock experienced a significant decline following the release of mixed Phase 3 trial results for Bristol Myers Squibb's (BMY) admilparant, a competing…
Sep 15, 2026 Corporate Catalyst Bearish Impact 90
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics (CTNM) shares are experiencing a significant sell-off after its Phase 2 MOONLIGHT-1 trial for JNJ-5120/PIPE-307, a major depressive disorder drug partnered w…
Sep 15, 2026 Corporate Catalyst Bearish Impact 55
Contineum Therapeutics shares are trading lower after Baird lowered its price target on the stock from $20 to $19.
The lowering of Contineum Therapeutics' price target by Baird from $20 to $19 is a direct corporate catalyst, signaling a slightly diminished outlook for the company's stock. While…
Sep 14, 2026 Corporate Catalyst Bearish Impact 95
Contineum Therapeutics shares are trading lower after the company announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint.
The failure of a primary efficacy endpoint in a clinical trial is a critical blow for a biotechnology company. This directly impacts Contineum Therapeutics' (CTNM) valuation, as th…
Sep 14, 2026 Corporate Catalyst Neutral Impact 85
Contineum’s Phase 2 MOONLIGHT-1 Trial Of JNJ-5120/PIPE-307 Did Not Meet Its Primary Efficacy Endpoint; Analyses Of The Data, Including Prespecified Exploratory Endpoints, Are Ongoing
Contineum Therapeutics' Phase 2 MOONLIGHT-1 trial for JNJ-5120/PIPE-307, a drug developed in partnership with Johnson & Johnson for Major Depressive Disorder, failed to meet its pr…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23
RBC Capital's analyst Brian Abrahams maintained an 'Outperform' rating on Contineum Therapeutics and raised the price target from $22 to $23. This action signals continued bullish …
Jul 31, 2026 Corporate Catalyst Bearish Impact 85
Contineum Therapeutics shares are trading lower after the company reported its Q2 financial results. The company announced a workforce reduction.
The headline indicates a significant negative corporate catalyst for Contineum Therapeutics. Poor Q2 financial results combined with a workforce reduction signal operational diffic…
Jul 30, 2026 Corporate Catalyst Bearish Impact 75
Contineum Therapeutics Implements Workforce Reduction For Its Research Team Including Chief Scientific Officer Daniel Lorrain
Contineum Therapeutics (CTNM) has disclosed a workforce reduction within its research team, notably including the departure of its Chief Scientific Officer, Daniel Lorrain. This ac…
Jul 30, 2026 Corporate Catalyst Bearish Impact 75
Contineum Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate
Contineum Therapeutics (CTNM) announced Q2 earnings per share of $(0.40), which significantly beat the analyst consensus estimate of $(0.48). This 16.67% beat, coupled with a 35.48…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.